science.org

MDMA-assisted therapy for PTSD is discussed in the context of an FDA rejection, with implications for how psychedelic therapy companies adjust their development plans. The piece frames the decision as a warning for sponsors pursuing approval and highlights how other firms plan to respond to avoid similar outcomes. The broader theme is risk management in clinical development for psychedelic-assisted mental health treatments, including regulatory strategy and future program adjustments following a setback.